Successful use of Upadacitinib in the child patient with very early onset of ulcerative colitis and refractory to therapy DOI Open Access
Olga V. Usoltseva, А. С. Потапов, А. О. Анушенко

и другие.

Russian Pediatric Journal, Год журнала: 2024, Номер 27(4), С. 291 - 299

Опубликована: Сен. 16, 2024

Ulcerative colitis is a chronic relapsing inflammatory disease of the colon with continuous spread lesions from rectum in proximal direction. The etiology unknown, but it assumed to be developed as result combination several factors. clinical picture often similar intestinal infection, which complicates timely diagnosis disease, especially children. Refractory standard therapy limits therapeutic options and increases frequency surgical interventions. However, emergence new drugs, such upadacitinib, opens up opportunities for treating patients studying effectiveness therapy. We present case successful treatment ulcerative upadacitinib child onset at age 6 months. purpose description show possibilities using janus kinase blocker Upadacitinib severe very early without effect previous importance emphasized.

Язык: Английский

Successful use of Upadacitinib in the child patient with very early onset of ulcerative colitis and refractory to therapy DOI Open Access
Olga V. Usoltseva, А. С. Потапов, А. О. Анушенко

и другие.

Russian Pediatric Journal, Год журнала: 2024, Номер 27(4), С. 291 - 299

Опубликована: Сен. 16, 2024

Ulcerative colitis is a chronic relapsing inflammatory disease of the colon with continuous spread lesions from rectum in proximal direction. The etiology unknown, but it assumed to be developed as result combination several factors. clinical picture often similar intestinal infection, which complicates timely diagnosis disease, especially children. Refractory standard therapy limits therapeutic options and increases frequency surgical interventions. However, emergence new drugs, such upadacitinib, opens up opportunities for treating patients studying effectiveness therapy. We present case successful treatment ulcerative upadacitinib child onset at age 6 months. purpose description show possibilities using janus kinase blocker Upadacitinib severe very early without effect previous importance emphasized.

Язык: Английский

Процитировано

0